P1171: REFLECT: PROSPECTIVE NON-INTERVENTIONAL STUDY ON THE EFFECTIVENESS AND SAFETY OF SANDOZ RITUXIMAB (SDZ-RTX) WITH CHOP FOR PATIENTS WITH PREVIOUSLY UNTREATED CD20-POSITIVE DI...

por Welslau, M., Kubuschok, B., Topaly, J., Otremba, B., Wolff, T., Bryn, G.
Publicado 2022

Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exp...

por Krop, I. E., Lin, N. U., Blackwell, K., Guardino, E., Huober, J., Lu, M., Miles, D., Samant, M., Welslau, M., Diéras, V.
Publicado 2015

Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group

por Kollmannsberger, C, Rick, O, Klaproth, H, Kubin, T, Sayer, H G, Hentrich, M, Welslau, M, Mayer, F, Kuczyk, M, Spott, C, Kanz, L, Bokemeyer, C
Publicado 2002

Efficacy, safety and quality-of-life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial

por Weiss, L., Karthaus, M., Riera-Knorrenschild, J., Kretzschmar, A., Welslau, M., Vehling-Kaiser, U., Pelz, H., Ettrich, T.J., Hess, J., Reisländer, T., Klein, A., Heinemann, V.
Publicado 2022

Patient-reported outcomes predict survival and adverse events following anticancer treatment initiation in advanced HER2-positive breast cancer

por Modi, N.D., Danell, N.O., Perry, R.N.A., Abuhelwa, A.Y., Rathod, A., Badaoui, S., McKinnon, R.A., Haseloff, M., Shahnam, A., Swain, S.M., Welslau, M., Sorich, M.J., Hopkins, A.M.
Publicado 2022